Form 8-K Valeant Pharmaceuticals For: Feb 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Valeant Pharmaceuticals (VRX) PT Lowered to $18 at Jefferies
March 1, 2017 7:46 AM ESTJefferies lowered its price target on Valeant Pharmaceuticals (NYSE: VRX) to $18.00 (from $22.00) while maintaining a Buy rating following Q4 result and outlook.
Analyst David Steinberg commented, "Q4 EPS of $1.26 was ~5% ahead of cons with revs just topping guidance ($2.28-2.38B) at $2.40B. More importantly,... More
